The latest price target for NovoCure (NASDAQ:NVCR) was reported by HC Wainwright & Co. on January 14, 2025. The analyst firm set a price target for $38.00 expecting NVCR to rise to within 12 months (a possible 42.38% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by HC Wainwright & Co., and NovoCure reiterated their buy rating.

The last upgrade for NovoCure Ltd happened on December 2, 2024 when Evercore ISI Group raised their price target to $30. Evercore ISI Group previously had an in-line for NovoCure Ltd.

The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.

While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a reiterated with a price target of $38.00 to $38.00. The current price NovoCure (NVCR) is trading at is $26.69, which is out of the analyst’s predicted range.